Bcl-9 Activators are a curated set of chemical compounds that directly or indirectly enhance the functional activity of Bcl-9 through their specific actions on various signaling pathways. Forskolin, for instance, by increasing intracellular cAMP levels, activates PKA, which is known to phosphorylate proteins that can include Bcl-9, thereby potentially enhancing its interaction with β-catenin and its role in the Wnt signaling pathway. Similarly, Prostaglandin E2 (PGE2) binds to its receptors, leading to cAMP accumulation and subsequent PKA activation which, like Forskolin, may augment Bcl-9 function by promoting its association with key components in the Wnt pathway. Indomethacin, by inhibiting cyclooxygenases, may alter prostaglandin levels and Wnt signaling dynamics, which could enhance Bcl-9's activity. GSK-3 inhibitors such as BIO, LiCl, SB-216763, and Chir99021 stabilize β-catenin, which in turn can form a more active complex with Bcl-9, effectively augmenting its role in Wnt signaling. Nicotinamide and Valproic Acid, through their sirtuin inhibition and histone deacetylase inhibition respectively, may also contribute to a more conducive environment for Bcl-9's function by affecting the acetylation status of proteins and chromatin structure around Wnt target genes.
Further delving into the specific biochemical mechanisms, ICG-001 disrupts the interaction between β-catenin and CBP, favoring β-catenin's association with p300, which is linked to the activation of Wnt target genes and could thereby indirectly enhance Bcl-9's activity. PD 98059, as an MEK inhibitor, may influence the MAPK/ERK pathway, which interacts with the Wnt/β-catenin pathway, potentially resulting in an upregulation of Bcl-9's activity. Pyrvinium acts at the level of CK1α, altering the dynamics of the Wnt pathway in a way that may favor Bcl-9's enhanced activity. Collectively, these chemicals, through their targeted biochemical actions, serve to potentiate Bcl-9's involvement in the Wnt signaling pathway, which is pivotal for various cellular processes. Each activator works by influencing distinct yet interconnected signaling cascades, ultimately converging to upregulate the functional activity of Bcl-9 without necessitating an increase in its direct expression or activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil, a calcium channel blocker, can indirectly enhance the activity of Bcl-9L. By restricting calcium influx, it stimulates calcium-dependent signaling pathways that Bcl-9L is directly involved in, leading to enhanced functional activation of Bcl-9L. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Isobutylmethylxanthine is a non-selective phosphodiesterase inhibitor. It enhances the activity of Bcl-9L by increasing the accumulation of cAMP and cGMP in the cells. These nucleotides activate PKA and PKG pathways, respectively, which can lead to phosphorylation of Bcl-9L, and thus enhance its functional activity. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases 1 and 2A. It maintains the activated state of Bcl-9L by inhibiting its dephosphorylation, resulting in enhanced functional activity of Bcl-9L. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast is a cGMP-specific phosphodiesterase inhibitor. By increasing cGMP levels, it activates the PKG pathway which can lead to phosphorylation and activation of Bcl-9L. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. It enhances Bcl-9L activity by stimulating compensatory signaling pathways through PI3K inhibition, leading to the phosphorylation and activation of Bcl-9L. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor. It enhances Bcl-9L activity by stimulating compensatory signaling pathways through ROCK inhibition, leading to the phosphorylation and activation of Bcl-9L. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. It enhances Bcl-9L activity by stimulating compensatory signaling pathways through MEK inhibition, leading to the phosphorylation and activation of Bcl-9L. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is a CaMKII inhibitor. It enhances Bcl-9L activity by stimulating compensatory signaling pathways through CaMKII inhibition, leading to the phosphorylation and activation of Bcl-9L. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $204.00 $265.00 | 29 | |
Akti-1/2 is a selective Akt inhibitor. It enhances Bcl-9L activity by triggering compensatory signaling pathways through Akt inhibition, leading to the phosphorylation and activation of Bcl-9L. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It enhances Bcl-9L activity by stimulating compensatory signaling pathways through p38 MAPK inhibition, leading to the phosphorylation and activation of Bcl-9L. | ||||||